Trial Profile
Corrona Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Adalimumab; Anakinra; Antirheumatics; Certolizumab pegol; Disease-modifying antirheumatics; Etanercept; Golimumab; Infliximab; Prednisone; Rituximab; Tofacitinib; Tumour necrosis factor inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CERTAIN
- 09 Nov 2021 Results (n=175) assessing treatment outcomes over a 12-month period among patients prescribed TNFi therapies as a first targeted treatment and stratified according to MSRC results presented at the ACR Convergence 2021
- 09 Nov 2021 Results of an analysis of Molecular Signature Response Classifier to predictive of inadequate response to TNFi presented at the ACR Convergence 2021
- 09 Nov 2021 Results (n=1698) assessing effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients presented at the ACR Convergence 2021